0.37

4.05% -0.0156

After Hours: .37

Clene Inc (CLNN)

Overview News Price History Option Chain Financials Discussions Forecast

Clene Inc stock is currently priced at $0.37, with a 24-hour trading volume of 311.13K. It has seen a -4.05% decreased in the last 24 hours and a +8.95% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.385 pivot point. If it approaches the $0.3647 support level, significant changes may occur.

Previous Close:

$0.3856

Open:

$0.392

24h Volume:

311.13K

Market Cap:

$47.52M

Revenue:

$654.00K

Net Income/Loss:

$-49.50M

P/E Ratio:

-0.6066

EPS:

-0.61

Net Cash Flow:

$-30.50M

1W Performance:

-4.27%

1M Performance:

+8.95%

6M Performance:

-18.52%

1Y Performance:

-59.78%

1D Range:

$0.37

$0.392

52W Range:

$0.25

$1.09

Clene Inc Stock (CLNN) Company Profile

Name

Clene Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

801-676-9695

Address

6550 South Millrock Drive, Suite G50, Salt Lake City

Employee

Twitter

Next Earnings Date

2024-05-29

Latest SEC Filings

CLNN's Discussions on Twitter

Clene Inc Stock (CLNN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy
May-02-22	Initiated	Canaccord Genuity	Buy
Sep-28-21	Initiated	Oppenheimer	Outperform

Clene Inc Stock (CLNN) Latest News

Trade Alert: The Independent Director Of Clene Inc. (NASDAQ:CLNN), David Matlin, Has Just Spent US$2.0m Buying ... - Yahoo New Zealand News

Yahoo New Zealand News

FY2028 Earnings Forecast for Clene Inc. (NASDAQ:CLNN) Issued By Roth Capital - MarketBeat

MarketBeat

Clene Inc Stock (CLNN) Financials Data

Clene Inc (CLNN) Revenue 2024

CLNN reported a revenue (TTM) of $654.00 thousand for the quarter ending December 31, 2023, a +38.27% rise year-over-year.

Clene Inc (CLNN) Net Income 2024

CLNN net income (TTM) was -$49.50 million for the quarter ending December 31, 2023, a -65.47% decrease year-over-year.

Clene Inc (CLNN) Cash Flow 2024

CLNN recorded a free cash flow (TTM) of -$30.50 million for the quarter ending December 31, 2023, a +30.98% increase year-over-year.

Clene Inc (CLNN) Earnings per Share 2024

CLNN earnings per share (TTM) was -$0.52 for the quarter ending December 31, 2023, a -15.56% decline year-over-year.

Clene Inc Stock (CLNN) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
General Resonance LLC	10% Owner	Apr 30 '24	Sale	0.42	13,000	5,416	15,326,712
General Resonance LLC	10% Owner	Apr 24 '24	Sale	0.33	10,000	3,278	15,349,712
General Resonance LLC	10% Owner	Apr 09 '24	Sale	0.39	22,500	8,674	15,428,212
MATLIN DAVID J	Director	Nov 10 '23	Buy	0.41	250,002	102,501	7,043,686
Stevens John Henry	Director	Jun 26 '23	Buy	0.80	316,455	253,164	800,204
Etherington Robert Dee	Chief Executive Officer	Jun 26 '23	Buy	0.81	25,000	20,250	25,000
Ugwumba Chidozie	Resigned as director 2/15/2023	Jun 16 '23	Buy	0.80	7,500,000	6,000,000	13,018,908
Mosca Alison	Director	Jun 16 '23	Buy	0.80	2,394,375	1,915,500	3,238,375
MATLIN DAVID J	Director	Jun 16 '23	Buy	0.80	1,500,000	1,200,000	6,793,684
Gay Jonathon	Director	Jun 16 '23	Buy	0.80	105,625	84,500	105,625

Clene Nanomedicine Inc., a biopharmaceutical company, develops technology solutions for drug development. The company develops Clean-Surface Nanosuspension, a technology that produces clean-surface nanocrystal medicines. Its technology also provides a platform for a pipeline of new drug candidates with application across a spectrum of diseases with unmet medical needs. The company focuses on demyelinating disorders and oncology. Clene Nanomedicine Inc. was incorporated in 2012 and is based in Salt Lake City, Utah.